Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF
GNMX
Chicago Board Options Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 425 Bush St, Suite 500 San Francisco CA United States of America 9410
- IPO Date
- May 6, 2026
- CIK
- 0002078265
- Similar Companies
- Business
- Corgi Genomics & Precision Medicine ETF (Cboe BZX: GNMX) is an actively managed thematic exchange-traded fund of Corgi ETF Trust I that seeks capital appreciation by investing primarily in publicly traded companies materially involved in the research, development and commercialization of genomics and precision-medicine technologies. The fund is managed by Corgi Strategies, LLC and provides investors with equity exposure across the genomics and biotechnology value chain, including DNA and RNA sequencing platforms; bioinformatics and computational-biology systems; gene-editing technologies; molecular and liquid-biopsy diagnostics; genetic testing services; targeted and precision therapeutics; biopharmaceutical research and development; clinical-data and healthcare-data platforms; laboratory instruments, reagents and consumables; and related life-sciences tools and services. Under normal market conditions, GNMX invests at least 80% of its net assets, plus borrowings for investment purposes, in companies associated with technologies intended to improve disease detection, stratify patients based on genetic, molecular or clinical characteristics, support treatment-selection decisions, develop targeted therapies and enable data-driven healthcare. The fund primarily serves investors seeking specialized exposure to healthcare innovation, biotechnology, life sciences and personalized medicine, with investments concentrated in the healthcare sector and principally in U.S.-listed equities, while retaining flexibility to invest across relevant global issuers. GNMX was launched on May 5, 2026, is domiciled in the United States and trades on Cboe BZX. Its portfolio includes companies spanning life-sciences tools, diagnostics and precision therapeutics, such as Thermo Fisher Scientific Inc., Moderna Inc., Vertex Pharmaceuticals Inc., Illumina Inc., Revolution Medicines Inc., Guardant Health Inc., 10x Genomics Inc. and Incyte Corp. The fund charges a 0.35% expense ratio. Its principal recent strategic development is its May 2026 launch as part of Corgi Funds’ expansion of actively managed thematic ETF offerings, which added 28 funds targeting structural-growth themes including genomics, aerospace, artificial intelligence cybersecurity, quantum computing, robotics and energy infrastructure; GNMX represents Corgi’s dedicated genomics and precision-medicine product within that broader launch.